Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy

Scott Zashin, Scott Zashin

Abstract

Sjogren's Syndrome is a chronic autoimmune disorder that causes the inflammation of the lacrimal and salivary glands, resulting in dryness of the eyes and mouth. In addition, fatigue and musculoskeletal pain, often described as aching, is very common. Treatment directed toward alleviating the fatigue and pain associated with Sjogren's is currently very limited. This report describes a case of a 47-year-old female with suspected Sjogren's based on long-standing dry eyes, dry mouth, joint pain, fatigue, elevated measures of inflammation, and a positive rheumatoid factor. She failed standard therapy but improved clinically with low-dose naltrexone therapy.

Keywords: autoimmune diseases; fatigue; joint pain; low dose naltrexone; sjogren syndrome.

Conflict of interest statement

I prescribe low dose naltrexone to patients in my medical practice

References

    1. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Younger J, Mackey S. Pain Med. 2009;10:663–672.
    1. Different effects of opioid antagonists on μ-, δ-, and κ-opioid receptors with and without agonist pretreatment. Wang D, Sun X, Sadee W. J Pharmacol Exp Ther. 2007;321:544–552.
    1. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Younger J, Parkitny L, McLain D. Clin Rheumatol. 2014;33:451–459.
    1. Glia as the 'bad guys": implications for improving clinical pain control and the clinical utility of opioids. Watkins LR, Hutchinson MF, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Brain Behav Immun. 2007;21:131–146.
    1. Low-dose naltrexone therapy improves active Crohn's disease. Smith JP, Stock H, Bigaman S, Mauger D, Rogosnitzky M, Zagon I. . Am J Gastroenterol. 2007;102:820–828.
    1. The effect of low-dose naltrexone on medication in inflammatory bowel disease: a quasi experimental before-and-after prescription database study. Raknes G, Simonsen P, Smabrekke L. . J Crohns Colitis. 2018;12:677–686.
    1. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. Mult Scler. 2008;14:1076–1083.
    1. Low dose naltrexone. 2018
    1. LDN Research Trust. 2018
    1. Dickson Dickson, Windham Windham, Smith Smith, et al. White River Junction, VT: Chelsea Green Publishing; 2016. The LDN Book.
    1. Moore E, Wilkinson S. Jefferson NC: McFarland & Company Inc; 2009. The Promise of Low Dose Naltrexone Therapy.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren